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Genome-wide microhomologies enable precise
template-free editing of biologically relevant
deletion mutations
Janin Grajcarek 1, Jean Monlong 2,5, Yoko Nishinaka-Arai 1, Michiko Nakamura1, Miki Nagai1,
Shiori Matsuo1, David Lougheed 3, Hidetoshi Sakurai1, Megumu K. Saito 1, Guillaume Bourque 2,3 &
Knut Woltjen 1,4*
The functional effect of a gene edit by designer nucleases depends on the DNA repair
outcome at the targeted locus. While non-homologous end joining (NHEJ) repair results in
various mutations, microhomology-mediated end joining (MMEJ) creates precise deletions
based on the alignment of flanking microhomologies (µHs). Recently, the sequence context
surrounding nuclease-induced double strand breaks (DSBs) has been shown to predict repair
outcomes, for which µH plays an important role. Here, we survey naturally occurring human
deletion variants and identify that 11 million or 57% are flanked by µHs, covering 88% of
protein-coding genes. These biologically relevant mutations are candidates for precise
creation in a template-free manner by MMEJ repair. Using CRISPR-Cas9 in human induced
pluripotent stem cells (hiPSCs), we efficiently create pathogenic deletion mutations for
demonstrable disease models with both gain- and loss-of-function phenotypes. We anticipate
this dataset and gene editing strategy to enable functional genetic studies and drug
screening.
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Editing genomic DNA with designer nucleases can havevarious functional outcomes depending on the endogenousrepair pathway recruited and type of mutation created at the
targeted locus (Fig. 1a). Classical non-homologous end joining (c-
NHEJ), which directly re-ligates DNA ends following a double
strand break (DSB), has been attributed to the efficient formation
of various insertions and deletions (indels), and has thus been
most commonly employed for gene disruption1–3. Yet, varying
indels can result in disparate phenotypic outcomes ranging from
silent mutations to the gain-of-function or loss-of-function (GOF
or LOF) of a protein4. In contrast, DSB repair (DSBR) by
homology directed repair (HDR) leads to outcomes dictated by
homologous templates. HDR may be used for precise gene edit-
ing, albeit at low efficiencies without selection5. An alternative
pathway, microhomology-mediated end joining (MMEJ),
involves end-resection and the alignment of microhomologous
sequences flanking DSBs. Subsequent removal of the intermediate
sequence results in deletions of predictable size and identity6.
Recently, MMEJ has been shown to play an important role in
DSB repair, even in cells competent for c-NHEJ and HDR
pathways6,7. The ability to create precise DSBR outcomes at a
target locus would increase the efficiency and applicability of gene
editing.
DSBR patterns can be influenced by a variety of factors
including cell type8–11 and cell cycle12. However, sequence con-
text surrounding the DSB is the best understood determinant.
DSBs induced by designer nucleases like transcription activator-
like effector nucleases (TALENs) and CRISPR-Cas9 show
replicable non-random repair patterns often based on the exis-
tence of microhomologies (µHs) neighboring the DSB8–11,13,14.
Bioinformatic tools have been developed that predict the pre-
valent repair outcomes at a target site based on the presence of
µHs and their distance from the DSB (heterology), and design of
CRISPR-Cas9 guide RNAs (gRNAs) to introduce DSBs between
µHs has been suggested as a strategy to knockout genes10,15 or to
correct mutations14. Still, the artificial introduction of a precise
frameshift mutation alone does not guarantee a functionally
predictable or even biologically relevant gene edit.
Deletions are the second largest class of mutations associated
with disease, accounting for 25% of human pathogenic genetic
variants annotated in the ClinVar database16. The observation
that certain locus-specific pathogenic copy number variations
(CNVs) and oncogenic chromosomal rearrangements are flanked
by µH implicates MMEJ in contributing to deletion and trans-
location variants in humans6,17. Nevertheless, a systematic ana-
lysis of naturally occurring µH-flanked genetic variants in the
human genome has yet to be completed.
In our current research, we create a tool called MHcut to
uncover the extent to which µH-flanked deletion mutations can
be found across the human genome. The µH-flanked variants
identified by MHcut in 57% of all human deletion mutations, are
candidates for recreation by harnessing precise and template-free
MMEJ. We apply this gene mutagenesis strategy to create isogenic
disease models in human induced pluripotent stem cells (hiPSCs),
which are uniquely suited for this purpose, as they are able to
differentiate into any tissue cell type18,19 and are predisposed to
MMEJ during DSBR11. Beyond demonstrating the value of MMEJ
precision in functional genomics, we provide a resource of
genome-wide µH-flanked deletion variants for further functional
genetic studies.
Results
The majority of human deletion mutations are flanked by µHs.
To first determine the extent to which µH is associated with
deletion variants in the human genome, we devised a tool called
MHcut which searches for homologous sequences at the ends of
annotated deletion variants (Fig. 1b,c, left). We applied MHcut to
genomic location and sequence data of deletion variants anno-
tated in dbSNP and ClinVar, the latter database containing
valuable information on the clinical significance of mutations.
MHcut aligns the 5′ and 3′ edges of each possible breakpoint that
would result in the annotated deletion to the current reference
human genome (GRCh38) and checks for maximum matching
sequence (Fig. 1b, left). The minimum requirement for MMEJ has
been proposed to be as few as 2 bp9,15. However, since analysis of
CRISPR-Cas9 deletion data suggests that no clear correlation
exists between repair outcomes following a DNA DSB and
homologous sequences less than 3 bp10, we opted for a more
stringent minimum length of 3 bp of µH to classify deletion
variants ≥3 bp in length as being µH-flanked. Despite observa-
tions that imperfect µH can lead to deletions of identical length
yet differing sequence matching either the 5′ or 3′ residual µH13,
we only considered consecutive sequence matches as µH in order
to conform specifically to annotated variant sequences.
Nearly 44 million deletion variants are represented in the
current versions of the dbSNP and ClinVar databases (Fig. 1c,
left). Strikingly, of the 19.3 million deletion mutations with a
minimum size of 3 bp, 57% (11.1 million) are flanked by perfect
µHs of at least 3 bp size, far exceeding the probability expected by
random base distribution (0.253= 1.56%). Surprisingly, for
deletions of at least 1 or 2 bp size with at least 1 or 2 bp flanking
µHs, homologous bases are detected in 75% (expected 0.251=
25%) and 67% (expected 0.252= 6.25%) of variants, respectively
(Supplementary Fig. 1a), implicating microhomology as a
common enriched characteristic of human annotated deletion
variants. We found a bias in µH-flanked variants towards short
deletions of 3 or 4 bp (Fig. 1d) with similarly sized µH (Fig. 1e),
such that 62% of variants have a heterologous sequence distance
of zero between them (Fig. 1f) revealing that µHs are usually
directly abutted. Regarding imperfect µH, allowance for a 1 bp
mismatch following a perfect stretch of 3 bp or more and
proceeding at least another single match only extended the
homology length for 16% of variants (Supplementary Fig. 1b).
The variant number could be only slightly extended to 11.9
million, or 62% of all deletions, if the definition of µH was relaxed
to allow at least one stretch of continuous µH of 3 bp or more,
emphasizing that 78% of variants are flanked by perfect µH
(Supplementary Fig. 1c, d). The 11.1 million µH-flanked deletions
≥3 bp were found to be evenly distributed across all chromosomes
(Supplementary Fig. 1e), with the vast majority residing in
intronic or intergenic locations (Supplementary Fig. 1f). Still,
98,848 variants can be found in exonic regions, with 88% of all
protein coding genes containing at least one µH-flanked deletion
mutation in an exon (Fig. 1g), making large functional genomic
screens feasible. The fact that less than 0.1% of µH-flanked
deletions are annotated for clinical significance shows that there is
an outstanding need for further functional exploration (Supple-
mentary Fig. 1g).
MHcut selects CRISPR sites for genome editing. In the interest
of generating more natural and disease-relevant mutations with
high efficiency, we further developed MHcut to select candidates
for creation by CRISPR-Cas9 cleavage and subsequent repair by
MMEJ. To orchestrate MMEJ deletions, MHcut searches the local
sequence of selected µH-flanked deletion variants for CRISPR-
Cas9 protospacer adjacent motifs (PAMs) positioned so as to
cause a DSB between the flanking µH, while retaining at least 3 bp
of µH on either side of the break (Fig. 1b, c, right). MHcut then
evaluates the upstream protospacer sequences of appropriately
positioned PAMs to act as unique gRNAs in the reference human
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Fig. 1 Analysis of human deletion alleles for flanking microhomologies (µHs). a Overview of double-strand break (DSB) DNA repair pathways and their
outcomes. homology-directed repair (HDR), classical non-homologous end joining (c-NHEJ), microhomology-mediated end joining (MMEJ). b Schematic
of the MHcut tool used to identify the microhomologous sequences. microhomologies (µHs, green) or nested µHs (red), SpCas9 PAM (underline) and DSB
location (pink bolt). c Numbers for variant data input and result of filters applied to the MHcut tool output. bp, base pairs. d Distribution of µH-flanked
deletion variants by deletion size. e Distribution of µH-flanked deletion variants by µH length. f µH-flanked deletion variants plotted by µH distance with µH
length indicated by fill color. g Percentage of protein-coding genes with µH-flanked deletion variant in exonic coding sequences
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genome. We initially chose to consider only ‘NGG’ sequences, the
canonical Streptococcus pyogenes Cas9 (SpCas9) PAM, since
SpCas9 represents the most commonly used and adaptable
nuclease with a well-characterized cleavage site +3 bp upstream
of the PAM20. Amongst the 11.1 million variants, 10% could be
targeted with a unique SpCas9 gRNA (Fig. 1c, right), matching
the predicted probability of ‘GG’ in positions +/−5, 6 on one side
of the deletion (12.5%) for abutted µH, yet biasing the data set
towards variants with more distant µHs due to the higher prob-
ability of identifying internal ‘NGG’ sites and unique gRNAs. Of
the 10% of variants (1,120,479) that could be targeted with a
unique SpCas9 gRNA, 3% are in exons (33,986). Of these var-
iants, 33% or 11,168 deletions would result in a frameshift. Of
note, 95% of these are variants of unknown significance (VUS).
PAM requirements may be modified in MHcut in order to
accommodate engineered SpCas9 variants (or alternative
CRISPR/Cas systems introducing a blunt-ended cut) and expand
the number of targetable variants. For example, allowing for
engineered xCas9 with a relaxed PAM requirement targeting
‘NG’, ‘GAA’ and ‘GAT’21, increases the targetable number of
variants to 33%.
For each gRNA and DSB site identified, MHcut also checks for
µHs concealed inside of the annotated deletion variant (Fig. 1b,
right). This step allows for the voluntary exclusion of variants
with nested µHs that could theoretically reduce the efficiency of
the desired deletion pattern, as µH with shorter intervening
heterology are expected to be used preferentially10,13,22. An initial
test at a locus in the GLA gene associated with Fabry disease
revealed that nested µHs indeed reduce the efficiency of the
targeted repair pattern (Supplementary Fig. 2a, b). Removing all
variants with nested µHs further reduces the candidate list to
about half (Fig. 1c, right). Additional filters are available to select
variants of interest and associated gRNAs based for example on
genomic location, clinical significance and prevalence of target
editing outcome as predicted by the inDelphi tool14. The output
of the tool with all filter options can be accessed online at https://
mhcut-browser.genap.ca/ (Supplementary Fig. 3a, b).
The creation of µH-flanked deletion variants is efficient. To test
if the loci identified by MHcut can indeed be repaired by MMEJ
to reproduce the patterns found in humans, we chose a small set
of candidate variants for proof-of-concept. The filter criteria for
targets included the availability of a NGG PAM and unique
gRNA for SpCas9, as well as pathogenic clinical significance, with
a view to creating demonstrable disease models. From the short-
list of 363 identified candidate variants (Fig. 2a), we chose targets
with short µH distances, as is representative of the overall dataset,
with varying µH lengths (Fig. 2b). Targets located on the X-
chromosome were selected to simplify genotyping of CRISPR
mutations in male ES and iPS cell lines.
Initially, a plasmid vector expressing SpCas9 and a single
gRNA was transfected into HEK293T cells or 1383D6 hiPSCs
(Supplementary Fig. 4a). Genomic DNA from the cell population
was isolated, and the target locus PCR amplified and sequenced.
The TIDE tool23 was used to deconvolute the pool of sequences,
revealing DNA repair patterns (Supplementary Fig. 4b). While
the overall indel ratio for HEK293T cells was almost double that
of hiPSCs at all targets (Supplementary Fig. 4c), likely reflecting
transfection efficiency, the ratio of the target MMEJ mutation was
on average one third higher in hiPSCs compared to
HEK293T cells (Supplementary Fig. 4d). Apart from the KDM6A
gene variant, the target MMEJ ratio in hiPSCs ranged between
70–100%. These results confirm that hiPSCs are especially suited
for a gene mutagenesis strategy relying on MMEJ repair
compared to a conventional cancer cell line.
With the goal of efficiently and accurately creating disease
models, we optimized our CRISPR-Cas9 transfection protocol in
human pluripotent stem cells. For that purpose, 1383D6 hiPSCs
and H1 human embryonic stem cells (hESCs) were transfected in
96-well format with ribonucleoprotein (RNP) complexes contain-
ing recombinant SpCas9 and one gRNA specific to each target
(Fig. 2c). Using RNP has the advantage of an acute activity and
reduced off-target cleavage compared to plasmid transfection24.
After 48 h, genomic DNA from the population was extracted and
analyzed as described above. While the overall indel ratio was
lower in H1 hESCs compared to 1383D6 hiPSCs, the indel ratios
consistently showed that overall mutagenicity varied between the
different targets (Fig. 2d). Importantly, the target MMEJ ratio was
highly similar between hESCs and hiPSCs where, apart from the
variant in the KDM6A gene, MMEJ ratios ranged between
70–100% (Fig. 2e). The low MMEJ ratio in KDM6A may be
influenced by a low GC-content (33%), ‘CA’ dinucleotide repeats,
or a T in position 4 upstream from the PAM, favoring +1 bp
insertions9,11. Although indel ratios at each target differed
between plasmid and RNP delivery, the target MMEJ ratios were
comparably high in pluripotent stem cells (Supplementary Fig. 4c,
d). In order to verify the functional relevance of these deletion
variants, we cloned hiPSCs with target MMEJ mutations in DYSF,
ALAS2 or FECH to establish disease models.
DYSF knockout by MMEJ disrupts protein expression. The
DYSFERLIN transmembrane protein encoded by DYSF affects
muscle fiber repair through regulation of membrane fusion
events25,26. Various DYSF allelic variants are pathogenic, result-
ing in the LOF conditions Miyoshi muscular dystrophy 1 and
limb-girdle muscular dystrophy type 2B, where patients experi-
ence progressive muscle weakness and atrophy. After concluding
that our DYSF target faithfully repaired by MMEJ in the pattern
of the natural variant (rs398123777), we established three DYSF-
5bpDel mutant clones made with the plasmid-based approach
(Supplementary Fig. 4a). All three selected clones are homo-
zygous for the 5 bp deletion (Fig. 3a, Supplementary Fig. 5a). The
DYSF-5bpDel mutation is predicted to be a LOF allele, as it
causes a frame shift (Gln957Profs) and a stop codon at amino
acid position 967 resulting in premature protein truncation
(Fig. 3b). The clonal DYSF-5bpDel cell lines were confirmed to
have retained their pluripotency as shown by OCT3/4 and
NANOG immunostaining (Supplementary Fig. 5b) and to have
no large chromosomal abnormalities in comparison to parental
1383D6 hiPSCs by SNP array (Supplementary Fig. 5c).
In order to observe the phenotypic consequences of the DYSF-
5bpDel MMEJ deletion, we introduced a piggyBac transposon
carrying the dox-inducible MYOD gene and mCherry reporter
into hiPSCs, selected neomycin resistant populations, and
differentiated them into a myogenic cell population over 5 days
of dox treatment (Fig. 3c)27,28. A previously established Miyoshi
myopathy patient hiPSC line served as a negative control27 and
parental 1383D6 hiPSCs served as a positive isogenic control.
Between 50–60% of each piggyBac-transposed hiPSC population
was mCherry positive indicating MYOD expression (Fig. 3d,
Supplementary Fig. 5d). On day 7, populations were immunos-
tained for Myosin Heavy Chain (MHC) to verify myogenic
differentiation (Fig. 3d). Whereas the parental isogenic hiPSCs
showed strong DYSFERLIN expression, all DYSF-5bpDel clones
showed a complete loss of DYSFERLIN similar to the patient
hiPSC line.
A MMEJ deletion in ALAS2 causes gain-of-function pheno-
type. Deletion variants are not always expected to result in gene
knockouts, but rather have the potential to generate phenotypes
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across a broad spectrum. In order to demonstrate this diversity in
genotype/phenotype correlation, we established disease models
for two target genes encoding enzymes in the heme synthesis
pathway. In erythroid cells, 5′-Aminolevulinate Synthase 2
(ALAS2) is the first enzyme of the heme synthesis pathway
producing 5-Aminolevulinic acid (5-ALA) (Fig. 4a). In other cell
types, the paralog ALAS1 is expressed exclusively. 5-ALA is
processed to Protoporphyrin IX (PPIX) by further enzymes.
Ferrochelatase (FECH), the last and rate limiting enzyme of the
pathway, integrates iron into PPIX to form heme. The ALAS2-
4bpDel mutation (rs387906472) causes a frame shift (Glu569-
Glyfs) and extension of the ALAS2 protein C-terminus (Fig. 4b)
resulting in a GOF allele with increased ALAS2 enzymatic
activity leading to an overproduction of 5-ALA and PPIX29.
FECH cannot process the resulting excess PPIX, which leads to
its accumulation (Fig. 4a). Patients with the rs387906472 var-
iant have abnormally elevated levels of PPIX in erythroid cells
causing photosensitivity of the skin and in extreme cases liver
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Fig. 2 Selected pathogenic target µH-flanked deletion mutations can be recreated with high precision in hiPSCs and hESCs. a Filtered MHcut tool output of
potential target pathogenic variants for the parameters shown. Graph at the right shows the distribution of target variants by µH distance with µH length
indicated by fill color. b Selected target variant list. µH (green), DSB location (pink bolt), SpCas9 PAM (underline). c Schematic of the experimental method
used to create MMEJ deletion alleles in 1383D6 hiPSCs and H1 hESCs. d Overall ratio of indel mutations found in the transfected hiPSC or hESC cell
populations. e Ratio of the target MMEJ outcome among total indels. Means ± s.e.m. for n= 3 biological replicates. Source data are in the Source Data file
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@We selected six clones for the ALAS2-4bpDel mutation,
three made with RNP and three made with plasmid transfection.
All clones were confirmed to have the precise MMEJ mutation
identical to the rs387906472 deletion variant (Fig. 4c, Supple-
mentary Fig. 6a), to be OCT3/4 and NANOG positive by
immunostaining (Supplementary Fig. 6b) and to have no large
chromosomal abnormalities in comparison to parental 1383D6
hiPSCs by SNP array (Supplementary Fig. 6c). Since the
ALAS2 gene encodes the erythroid-specific form of the 5-
Aminolevulinate synthase31,32, we differentiated ALAS2-4bpDel
hiPSC clones to erythroid cells following an established protocol,
with modifications (Fig. 4d)33,34. On day 26 of the differentia-
tion, expression of the mature erythroid cell markers CD71 and
CD235a was checked by FACS and activation of ALAS2
expression was confirmed by qPCR (Fig. 4e, f). The CD71 and
CD235a double positive cell populations of the six ALAS2-
4bpDel mutant clones, ranging from 70–90% of the total
population (Fig. 4e), were shown by FACS to accumulate PPIX
compared to the parental isogenic hiPSC (Fig. 4g). In addition,
for 5 analyzed ALAS2-4bpDel clones, PPIX extraction from
whole cell populations by ethyl acetate/acetic acid35 showed a
14-fold to 30-fold increase of PPIX content compared to
erythrocytes from isogenic parental hiPSCs (Supplementary
Fig. 6d). In conclusion, the ALAS2-4bpDel mutant hiPSC clones
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Fig. 3 @Target variant associated with muscular dystrophy created by MMEJ recapitulates DYSFERLIN loss-of-function. a Sequence verification of a precise
5 bp deletion mutation in DYSF. Deletion (dotted line), DSB location (pink bolt), µH (green), SpCas9 PAM (underline). b Altered protein sequence of
DYSFERLIN caused by the 5 bp deletion mutation. c Schematic of the experimental procedure to induce myogenic differentiation in hiPSCs by overexpression
of MYOD from a piggyBac transposon. Differentiation day (D). d Immunostaining for DYSFERLIN and MHC in differentiated hiPSC populations. Comparison
of the isogenic parental cell line, three derived clones carrying the disease mutation and a muscular dystrophy patient derived hiPSC cell line. Scale bar
indicates 100 µm; ratio of mCherry+ cells measured by FACS in corresponding electroporated (EP) hiPSC populations indicated on the right
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A MMEJ deletion in FECH causes loss-of-function phenotype.
Finally, we established a LOF disease model for FECH, the last
enzyme in the heme synthesis pathway (Fig. 4a). The
rs786205248 deletion variant results in a frame shift (Tyr194-
Leufs) and premature stop codon at amino acid position 208
rendering the protein non-functional (Fig. 4b)36. Patients with
the rs786205248 variant have a condition called Erythropoietic
Protoporphyria (EPP). Similar to XLP, EPP is associated with
photosensitivity of the skin and an increased risk of liver damage
due to an accumulation of PPIX in cells (Fig. 4a). In humans this
particular mutation of FECH is autosomal dominant, and can
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experiment no hiPSC clones presented homozygosity for the 5 bp
deletion mutation or the second most common mutation, a 1 bp
insertion (Supplementary Table 1), either of which induce distinct
frameshifts leading to premature stop codons. Our data suggest
that FECH mutations are generally homozygous lethal in hiPSCs,
which may account for the reduced indel ratio observed (Fig. 2d).
Three clones made by RNP transfection were confirmed to be
heterozygous with one normal allele and the precise MMEJ
deletion on the other allele (Fig. 4c, Supplementary Fig. 6a). All
three clones retain their pluripotency as shown by OCT3/4 and
NANOG immunostaining (Supplementary Fig. 6b) and to have
no large chromosomal abnormalities in comparison to parental
1383D6 hiPSCs by SNP array (Supplementary Fig. 6c).
Following differentiation of the FECH-5bpDel clones to
erythrocytes (Fig. 4d, e) and observing an upregulation of ALAS2
and FECH expression (Fig. 4f), we could not detect increased
levels of PPIX compared to erythrocytes from normal isogenic
parental hiPSCs, neither by FACS (Fig. 4g) nor by plate reader
(Supplementary Fig. 6d). This is consistent with the results found
in EPP patient fibroblasts37, and suggests that the FECH enzyme
amount produced by heterozygous mutant cells is still sufficient
to process PPIX under in vitro conditions. In addition,
insufficient maturation of the heme synthesis pathway for
in vitro differentiated erythroid cells may complicate comparison
to in vivo disease conditions. Nevertheless, we could trigger a
PPIX accumulation phenotype in undifferentiated FECH-5bpDel
hiPSC clones by stressing the heme synthesis pathway through
supplementation with additional 5-ALA in the culture medium37.
The amount of PPIX in the cells increased in a dose-dependent
manner as shown by FACS (Fig. 4h). In the absence of 5-ALA
and at 0.025 mM 5-ALA, only background fluorescence was
detectable. Starting from 0.05 mM 5-ALA, PPIX accumulation
was detectable in all cells. A noticeable difference between the
normal isogenic parental hiPSCs and the FECH-5bpDel clones
was detected from 0.1–0.5 mM 5-ALA, where all three FECH-
5bpDel clones had higher accumulation of PPIX ranging from
22–37% (Fig. 4h). This result, taken together with the fact that no
homozygous hiPSC could be obtained, indicate that our MMEJ
deletion alleles recapitulate the EPP phenotype.
Assessing the scope of targetable variants. The length of het-
erology is known to negatively affect the efficiency of MMEJ
repair, with suggested limits ranging from 5 bp10 to around 15
bp11. While over 80% of the variants in the MHcut dataset are
either directly abutted or have a very short distance of 0–2 bp
(Fig. 1f), the strict need for a unique Cas9 gRNA biases the set of
targetable variants towards larger distances, with only 45% of
variants having a µH distance of 0–2 bp. We expect this bias to be
mitigated by using engineered Cas9 or orthologues with different
PAM requirements.
To assess the impact of increasing µH-distance on the
efficiency of template-free creation of the MHcut variants, we
first analyzed the MHcut dataset with the inDelphi editing
prediction tool14. The mean prevalence predicted by inDelphi
(average score from available mESC, HCT116, HEK293, K562,
U2OS cell data) for all MHcut variants with available Cas9 gRNA
indicates that, depending on µH length, µH distances between 4
and 10 bp are expected to cause the MMEJ ratio of the target
deletion to drop below 20% on average (Supplementary Fig. 7a).
To validate this data in hiPSCs, we chose a set of candidate
variants with µH distances between 3 and 10 bp (Supplementary
Fig. 7b) from our short-listed pathogenic variants (Fig. 2a), and
transfected RNP complexes as described above (Fig. 2c). While
we could not identify a clear limit for µH-distance impacting the
target MMEJ ratio, we observed the highest MMEJ ratio (91%) for
a novel variant in TSC2 with a µH distance of 7 bp
(Supplementary Fig. 7d). As observed for GLA (Supplementary
Fig. 2a), these data suggest that larger µH distances are more
likely to contain nested µHs, interfering with target deletion
creation. Importantly, the results also show that low gRNA
efficiencies are another major obstacle in creating the target
deletion (Supplementary Fig. 7c, d), supporting the need for
reliable gRNA prediction software or engineered Cas9 variants to
fully explore the MHcut dataset.
Discussion
Although recent research into nuclease mediated DSBR outcomes
has highlighted the importance of the MMEJ pathway6,7, the
extent to which µH can be found at naturally occurring deletion
junctions had not yet been systematically investigated. Con-
sidering the importance of sequence context in predicting
mutation outcomes8–10,14,15, knowledge of extant µH can greatly
enhance biological relevance, functionality, efficiency and preci-
sion of gene edits. While DNA repair outcome prediction tools,
like inDelphi14, use sequencing data resulting from artificially
introduced DSBs to train their machine learning algorithms, our
MHcut tool takes a different approach of analyzing the sequence
of existing deletion variants in the genome for the presence of µH.
In this sense, our research complements the available prediction
tools (Fig. 5), by enabling researchers to reference mutations
detected in the human population to modify their target gene,
instead of introducing an artificial gene edit. Meanwhile, the
prediction algorithms allow for the selection of the MHcut can-
didate variants with the highest probability for efficient recrea-
tion. The MHcut dataset can also contribute a relevant list of
endogenous target loci for creating training datasets for predic-
tion algorithms in the future. Here, we not only uncover the
extent to which deletion mutations in the human genome are
flanked by µH, which to our knowledge was not previously
possible with currently accessible tools, we also prove the feasi-
bility of our gene editing approach using DSBR by MMEJ to
recreate the annotated disease alleles in hESCs and hiPSCs. Using
this method, new disease models including appropriate isogenic
Fig. 4 Erythropoietic protoporphyria disease models created by MMEJ display ALAS2 gain-of-function and FECH loss-of-function. a Phenotypic
consequences of ALAS2 gain-of-function and FECH loss-of-function mutations on the accumulation of metabolites in the heme synthesis pathway. 5-
Aminolevulinic acid (5-ALA), Protoporphyrin IX (PPIX). b Altered protein sequences of ALAS2 and FECH caused by deletion mutations. c Sequence
verification of a precise 4 bp deletion mutation in ALAS2 and a 5 bp deletion in FECH generated by either plasmid or RNP transfection. Deletion (dotted
line), DSB location (pink bolt), µH (green), SpCas9 PAM (underline). d Schematic for cell culture conditions during erythroid differentiation. Differentiation
day (D). e Ratio of erythroid cells in differentiated hiPSC populations on D26, as indicated by CD235a-FITC and CD71-APC markers, measured by FACS.
f Gene expression levels measured by qRT-PCR of ALAS2 and FECH in undifferentiated cells and D26 cell populations normalized to cord blood cells.
g PPIX-Qdot® 605 fluorescence intensity in erythroid cell populations of mutant and normal cell lines on day 26, measured by FACS. h Dose-response
curve of PPIX accumulation in response to 5-ALA treatment in undifferentiated hiPSC disease model clones and the isogenic parental line. Median
fluorescence intensity of PPIX-Qdot® 605 measured by FACS and normalized to the parental cell line at 0.5 mM 5-ALA. Means ± s.d. for n= 3 biological
replicates. Source data are in the Source Data file
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controls can be established efficiently and quickly with gRNAs
suggested by the MHcut tool.
MHcut identified 11 million deletion mutations of 3 bp or
more that are flanked by µH of at least 3 bp or more. However,
only 10% of variants are expected to be targetable by SpCas9. The
limited number of gRNAs per MHcut variant and the prevalence
of the target editing outcome, especially for variants with longer
µH distances, are a constraint on the scope of targetable variants.
We found gRNA efficiencies to be highly variable and therefore
recommend prioritizing the gRNAs identified by the MHcut tool
not only with tools for editing outcome prediction, but also with
state-of-the-art gRNA on-target and off-target efficiency evalua-
tion software (Fig. 5) to maximize the efficiency of target variant
creation. Using other engineered CRISPR-Cas9 variants with
flexible PAM sites38,39, as well as TALENs or Zinc-finger
nucleases (ZNFs), the genome-wide target space could be sig-
nificantly increased. In addition, the overall number of candidate
variants with µH of at least 3 bp or more could be further
increased from 11 million by relaxing the criterion for mis-
matches in the µH. In order to accommodate disease mutations
flanked by µHs with mismatches6, the MHcut tool can be
adjusted to allow for a customizable number of mismatches.
The fact that the majority of deletion mutations existing in the
human genome are flanked by µHs hints at the extent to which
MMEJ repair might contribute to genetic variation in humans. It
has been demonstrated that MMEJ operates in the context of c-
NHEJ and HDR competent cells. Other research groups have
found gRNAs that induce a specific MMEJ deletion in up to
80–90% of mutant alleles in vertebrate cells10 and up to 30–40%
in HEK293T cells9,10. Our research in pluripotent stem cells
shows that up to 100% of SpCas9-induced mutations can be
attributed to a specific µH, but appear dependent on sequence
features such as µH length and distance. Although in vitro results
cannot retrospectively prove the natural cause of these variations,
the phenomenon observed by our MHcut analysis suggests that
MMEJ might be more prevalent in human cells than initially
expected6,7,40. Based on this data trend, we suspect that additional
µH-flanked variants might be found in sequencing data amassed
by efforts such as the 100,000 Genomes Project, Genome in a
Bottle, SwissVar or the GenomeDenmark platform.
Hereafter, disease models created in hiPSCs by MMEJ can be
used for drug screening and functional analysis in an isogenically-
controlled genetic background. Concretely, the effect of Succi-
nylacetone on the accumulation of Protoporphyrin41 could be
tested in our XLP erythroid cells. Moreover, high MMEJ ratios
with up to 100% accuracy found for longer µHs suggest that
applications for gene therapy are possible, especially since MMEJ
has been shown to work under in vivo conditions in vertebrates10.
Potential targets for gene therapy by MMEJ would result in alleles
overcoming disease phenotypes caused by microduplications
like familial hypercholesterolemia14, frameshift mutations like
Duchenne muscular dystrophy42, or dominant mutant alleles
like in XLP.
In the future, the uncovered variety of naturally occurring
mutations flanked by µH will act as a resource to help expand our
understanding of parameters influencing DSBR pathway choice
(e.g., µH length, deletion length, µH distance, genomic location,
etc.). In addition, they can be utilized to elucidate the function of
DNA repair pathway components. Inhibiting or enhancing
individual components can accelerate research into MMEJ
pathway genetics and kinetics, opening up the possibility of fur-
ther increasing the efficiency of MMEJ induced mutations9,14,43
for rational application.
Methods
MHcut tool. For a deletion entry, the variant’s sequence and both flanking
sequences are retrieved. Microhomology (µH) is tested for both flanking config-
urations: 5′ flanking region with 3′ variant sequence and 3′ flanking region with 5′
variant sequence. µH is extended as much as possible allowing for at most one
mismatch. Both the full µH and the first stretch of exact µH is saved. Summary
metrics on the µH include homology, distance between µHs and GC content. The
µH is scored as the sum of matches in the full µH and the length of the first stretch
of exact µH. The flanking configuration with the strongest score is then selected for
further analysis. Of note, a variant of the tool was implemented to report results for
both flanking configurations but showed minimal differences. In many cases the
same deletion can be represented by different coordinates and can be shifted
without affecting the deletion represented. For this reason, MHcut will also shift
each deletion as much as possible and pick the coordinates that result in the
longest µH.
Once the µH is defined, we select potential gRNAs. First, we look for PAMs that
would result in a cut within the variant sequence, excluding the first 3 bp of the µH
sequence. To filter cuts that would lead to large heterologies in large deletions, only
cuts within 50 bp of the µHs are considered. Of note, this output still allows to
design experiments with two cuts, one close to each µH, to recreate large deletions.
For each position found, we save the PAM, strand, protospacer sequence and
distance between the cut and both µHs.
Second, each gRNA is then tested for exact off-target candidates (0 mismatches)
in the genome. The protospacer sequence and PAM are aligned to the genome
using Jellyfish44 for a fast exact alignment. In the absence of off-target candidates,
the guide and PAM sequences should align to a unique position in the genome.
Finally, MHcut also checks for µHs nested inside of the annotated deletion
variant, that could be preferred over the target µH, using the Bae et al. script15 for
each possible cut position. An exact µH on each side of a cut, at least 3 bp long and
closer to each other than the target µHs is considered to be a nested µH. The
number of nested µHs and strength are recorded for each guide and summarized at
the variant level.
In addition, MHcut calculates the predicted prevalence of each variant among
repair outcomes using the inDelphi algorithm14 for each cut position and for each
of the 5 cell types provided by inDelphi. The predicted prevalence is recorded for
each guide and summarized for the best guide at the variant level.
MHcut outputs contain results at the variant level with µH metrics and the
number of guides found at the different stages of the workflow, and at the guide
level with information about guides with no perfect off-targets (Supplementary
Table 2).
dbSNP and ClinVar analysis. Deletions were extracted from dbSNP45 (October
28, 2018 release) and ClinVar46 (July 1, 2018 release) on the GRCh38 genome










Check if targetable µH-flanked variants
exist and export guide RNA list
Prioritize guide RNAs based on
predicted DNA editing outcome
Prioritize guide RNAs based on
predicted “on-target” & “off-target” activity
Procure guide RNA and Cas9





Fig. 5 MHcut tool complements existing tools for selecting a suitable gene
editing target and gRNA. (*MHcut tool contains the editing prediction for
the target deletion from the inDelphi editing outcome prediction tool14)
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After merging both databases, the variants were annotated according to their
overlap with the gene annotation from Gencode v2847, as either exonic, intronic,
within UTRs, or intergenic. The dataset consisted of 43.7 M deletions once
duplicates had been removed. We then used the MHcut tool described above to
identify potential microhomology and CRISPR cuts that could recreate the
deletions. Due to the scale of the input data, we used Jellyfish44 (v2.2.6) to test for
off-target guides. The main results presented here were produced for SpCas9’s
PAM (NGG) and allowing at most one consecutive mismatch in the
microhomology. Eventually, MHcut was also run on the full dataset when using
xCas9’s PAMs (NGN, GAA or GAT)21. We created the pathogenic category in
clinical significance by summarizing all variants that contain the word pathogenic
in their label. Data analysis was conducted in R and Excel.
MHcut browser data portal. The variant-level and guide-level output were parsed
and inserted into a PostgreSQL database. The portal interface was written in
JavaScript with the D3 library, using a Python server written with the Flask fra-
mework to query the database. Thorough indexing and caching of results ensured
that the queries scaled to millions of data points. The data portal is available at
https://mhcut-browser.genap.ca/.
Cell culture. HEK293T cells (Thermo Scientific, USA) were maintained in culture
medium containing DMEM, 10% FBS, penicillin-streptomycin, and L-glutamine.
HEK293T cells were passaged every 3–4 days.
Undifferentiated hESCs and hiPSCs were cultured under feeder-free
conditions48. H1 hESCs49 (WA01, WiCell, USA) and 1383D6 hiPSCs50 (Center for
iPS Cell Research and Application, Japan) were maintained in StemFit AK02N
(AJINOMOTO) in 6-well or 96-well tissue culture dishes coated with Laminin
iMatrix-511silk (Nippi), or iMatrix-511 (Nippi), respectively (0.5 µg/cm2). During
the passage, addition of 300 µL of Accumax (Innovative Cell Technologies) for 6-
well or 30 µL for 96-well and incubation at 37 °C for 15 min, followed by
dissociation through pipetting were used to detach the cells. Cells from each surface
were collected in 700 µL or 100 µL medium containing 10 µM ROCK inhibitor, Y-
27632 (Wako). The Countess II FL Automated Cell Counter (Thermo Fisher
Scientific) was used to count cells using trypan blue exclusion. For a typical cell
passage, 1 × 104 cells were seeded in a 6-well plate in media containing Y-27632.
ROCK inhibitor was removed on the second day of culture. On the seventh day
after passage, cells reached 80% confluency and were passaged again. Frozen stocks
were prepared by resuspending cells at 1 × 106 viable cells per 1 mL STEM-
CELLBANKER (Takara) and freezing 200 µL cell suspension in a cryogenic tube in
liquid nitrogen. One vial of cell stock was defrosted per well of a 6-well plate in
media containing Y-27632. Cells were regularly tested for mycoplasma.
To induce Protoporphyrin IX (PPIX) accumulation in hiPSCs, undifferentiated
1383D6 cells, and derived FECH-5bpDel clones, 5-Aminolevulinic Acid (5-ALA)
was added to the cell culture medium at 0.025 mM, 0.05 mM, 0.075 mM, 0.1 mM,
0.25 mM, and 0.5 mM concentrations. Medium was changed daily until the cells
were analyzed using flow cytometry on the fifth day as described below.
Plasmid construction. Supplementary Table 3 provides a list of sequence-verified
plasmids used in this study. For plasmid gene editing, sgRNA oligonucleotides were
annealed and cloned into pSpCas9(BB)-2A-Puro V2.0 plasmid (pX459v2, a gift
from Feng Zhang, Addgene plasmid #62988) linearized with BbsI as described by
Ran et al.51. In brief, equal volumes of 100 µM oligos were annealed by heating to
95 °C for 5 min, followed by a slow cool down and a 1:200 dilution in water. 100 ng
linearized vector were then mixed with 2 µL annealed oligo and 4 µL Ligation Mix
(Takara) and incubated at 16 °C for 30 min. The mix was then transformed into
competent bacteria using heat shock at 42 °C. Plasmid DNA from clones was
extracted using the Wizard® Plus SV Minipreps (Promega) Kit according to the
manufacturer’s instructions. Primers used for cloning are listed in Supplementary
Table 4. Sequences were verified using the U6 primer ‘GAGGGCCTATTTCC-
CATGATTCC’ (dna790) and Sanger sequencing described below. Complete
sequences are available upon request.
Cell transfection. For plasmid transfection into HEK293T cells, 1 µg of the
pX459v2 vector containing the respective sgRNA were prepared in 150 µL OPTI-
MEM I reduced-serum medium (Invitrogen) containing 6 µL Fugene HD trans-
fection reagent (Promega). After 15 min incubation, 300 µL cell suspension con-
taining 3 × 105 cells were added and cells were transferred to a 6-well culture plate.
Genomic DNA was extracted three days after transfection.
For plasmid transfection into 1383D6 hiPSCs, 3 µg of plasmid were transfected
by NEPA21 (Nepa Gene Co., Ltd) electroporation with 125 V and a poring pulse
length of 5 ms into 1 × 106 cells in single-cell suspension in Opti-MEM medium
(Thermo Fisher Scientific), as described50. Half of the electroporated cells were
plated in a 60 mm cell culture dish well in medium containing Y-27632. On the day
after electroporation, Y-27632 was removed and in the case of pX459v2 plasmids
0.5 µg/mL puromycin (Sigma-Aldrich) was added for 48 h. Genomic DNA was
extracted nine days after transfection.
For RNP transfection H1 hESCs and 1383D6 hiPSCs were seeded 5 days before
the transfection as described above. On the fifth day cells were harvested at 50–60%
confluency and diluted to 2 × 105 cells per mL for reverse transfection using
LipofectaminTM Stem transfection reagent (invitrogen) as per the manufacturers
recommended protocol. Alt-R CRISPR-Cas9 V3 protein, synthetic tracrRNA, and
crRNAs (Supplementary Table 5) were purchased from IDT. First, equimolar
amounts of crRNA and tracrRNA in the provided duplex buffer were mixed and
heated to 95 °C for 5 min and allowed to cool to room temperature to form the
gRNA. Both gRNA and Cas9 protein were diluted to 1 µM in OPTI-MEM (Gibco).
Subsequently, equimolar amounts of 500 ng Cas9 protein and gRNA were mixed in
a final volume of 25 µL OPTI-MEM per reaction and incubated for 20 min at room
temperature (RT) to form the RNP complex. The transfection reagent was diluted
at 1 µL in 24 µl OPTI-MEM per reaction. RNP complexes were added to diluted
transfection reagent and incubated for 20 min at RT. Per reaction in 96-well
format, 50 µL transfection mixture were mixed with 100 µL cell suspension (20,000
cells) in media containing Y-27632. As a negative control cells were transfected
with gRNA only or Cas9 protein only. Cells were cultured for 48 h before being
harvested for analysis as described above.
For picking clones, part of each RNP-treated cell population was passaged into a
6-cm dish at clonal density (600 cells). Colonies were isolated manually with a
micropipette and cultured in 96-well format as described above.
Genomic DNA extraction. Cells were harvested as described above. For genomic
DNA extraction the cells were subsequently washed twice in PBS, before the DNA
was extracted using different protocols.
Genomic DNA from plasmid transfections and selected hiPSC clones was
extracted from 0.5–1 × 106 harvested cells using the DNeasy Blood and Tissue Kit
(Qiagen) according to the manufacturer’s instructions.
For sequence screening of hiPSC clones picked in 96-well format, genomic
DNA was isolated by adding 50 µL plate lysis buffer52 (10 mM Tris-HCl, pH 7.5,
10 mM EDTA, 0.5% Sarcosyl, 10 mM NaCl, and 1 mg/mL Proteinase K) and
incubating overnight at 55 °C. Subsequently, 100 µL ice cold solution of 100%
EtOH and 5M NaCl were added for DNA precipitation. The samples were
vortexed, incubated for about 1 h and then centrifuging at 9,100 xg for 15 min.
After removing the supernatant and rinsing twice with 70% EtOH the DNA was re-
suspended in TE pH 8.0, according to expected DNA concentration52.
Cells transfected with RNP were cultured for 48 h and then lysed using EpiBio
Quick Extraction solution (Epicenter). Briefly, cells were harvested as described
above and transferred to a 96-well PCR plate. After washing twice with PBS, 50 µL
of DNA extraction solution was added per well and the plate was vortexed
vigorously for 15 s. After incubating the plate for 6 min at 65 °C, it was vortexed
again, followed by a final incubation at 98 °C for 2 min. The lysates were used
directly for PCR or stored at −30 °C.
Sanger sequencing. To verify the DNA repair outcome in the transfected cell
populations and picked clones, a genomic region of 700–800 bp surrounding the
target site was PCR amplified using the primers listed in Supplementary Table 6.
Primers were designed using NCBI Primer-BLAST with optional settings for
human repeat filter, SNP handling, and primer pair specificity checking to the H.
sapiens reference genome. PCR was performed using Phusion Hot Start II DNA
Polymerase (Thermo Scientific) on a Veriti 96-well Thermal Cycler (Applied
Biosystems) according to the manufacturer’s instructions. Specific PCR conditions
are available upon request.
Prior to sequencing, PCR products were treated with ExoSAP-IT Express Reagent
(Affymetrix) according to the manufacturer’s instructions. The BigDye Terminator
v3.1 Cycle Sequencing Kit (Applied Biosystems) was applied for DNA sequencing,
followed by ethanol precipitation. Subsequently, the sequencing was performed on a
3130 × 1 Genetic Analyzer (Applied Biosystems). Sequence alignments were
conducted using Snapgene v.3.1.4 or higher (GSL Biotech LLC.). Sequence trace files
with poor base calling confidence were excluded from further analyses.
TIDE analysis. To deconvolute the mixed sequences resulting from various DNA
repair outcomes in the cell populations we performed TIDE analysis using the R
script provided by the authors23. The deletion size window was extended to the
maximum of 50 bp to accommodate larger deletions. The right boundary of the
deconvolution window was adjusted individually by target to exclude low-quality
sequence trace regions at the end of the amplicon. The p-value, calculated with a
two-tailed t-test of the variance–covariance matrix of the standard errors23, was
adjusted to p < 0.05 from the default p < 0.001 to include possible rare repair events
in the analysis. The remaining parameters were set to default or allowed to adjust
automatically.
SNP array. Genomic DNA from iPSC clones modified by gene editing were
genotyped using an Infinium OmniExpress-24 v1.2 and v1.3 (Illumina) SNP array
according to the manufacturer’s recommendations. Median probe spacing is
around 2 kb. Array scanning was performed on an iScan Bead Array Scanner
(Illumina). Scanned data were processed using Illumina GenomeStudio (2011.1 for
v1.2 and 2.0.4 for v1.3) with human genome Build 37 and FinalReports were
exported according to the manufacturer’s protocol. CNV call was done using a
combination of PennCNV53 (1.0.3), GWASTools54 (v1.2.R), and MAD55 (1.0.1).
Karyograms were prepared using GenomeJack (Mitsubishi Space Software).
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Myogenic differentiation. Doxycycline-inducible MyoD-hiPSCs were generated
and differentiated to myogenic cells as previously described27,28 (Fig. 3c). In brief,
hiPSCs were electroporated with 1 µg each of PB-TAC-ERN-hMyoD and pCAG-
PBase, as described above. Two days after electroporation 175 µg/mL Neomycin
was added to the medium. On day 12, cells were passaged.
To check the percentage of the population expressing MyoD, undifferentiated
hiPSCs were induced for 48 h with 1 µg/mL doxycycline, before mCherry
expression was confirmed by flow cytometry, as described below.
For myogenic differentiation, 3 × 105 of the dissociated MyoD-hiPS cells were
seeded onto a Matrigel (BD Biosciences) coated 6 well-plate in AK02N medium
containing Y-27632 at day 0. On day 1, culture medium was replaced by Primate
ES Cell Media (Reprocell). On day 2, MyoD expression was induced by adding
1 µg/mL doxycycline. On day 3, the culture medium was changed to differentiation
medium containing alpha Minimal Essential Medium (αMEM; Nacalai Tesque)
with 5% KSR (Invitrogen) and 1 µg/mL doxycycline. Medium was changed daily
until cells were used for immunohistochemistry on day 7.
Immunohistochemistry of cultured cells. For staining of the pluripotency mar-
kers NANOG and OCT3/4, medium sized hiPSC colonies were treated with a
solution of 4% Paraformaldehyde (PFA) PBS for 10 min at room temperature (RT).
Cells were permeabilized using a solution of 0.1% Triton X-100 in PBS for 10 min
at RT, followed by a blocking step in 3% bovine serum albumin (BSA) in PBS for
60 min at RT. The primary antibodies, Nanog (D73G4) XP Rabbit mAb
(#4903S, Cell Signaling) (1:500) and Purified Mouse Anti-Oct3/4 (#611203, BD
Biosciences) (1:250) were prepared in blocking solution and cells were incubated
overnight at 4 °C. After a washing step, cells were incubated for one hour at RT
with the respective secondary antibodies Alexa Fluor 546 goat anti-rabbit immu-
noglobulin G (IgG) (H+ L) (#A11010, Life Technologies) (1:500) and Alexa Fluor
546 goat anti-mouse IgG (H+ L) (#A11030, Invitrogen) (1:500) prepared in
blocking solution containing 1 µg/mL DAPI. After 3 subsequent washing steps, the
cells were observed under a fluorescence microscope. Phase-contrast and fluores-
cence images were acquired on a BZ-X710 (KEYENCE) using appropriate filters
and exposure times.
Differentiated myogenic cells were fixed with a solution of 2% PFA in PBS
for 10 min at 4 °C, followed by a treatment with MeOH:H2O2 (100:1) at 4 °C for
15 min. The cells were blocked with Blocking One (Nacalai Tesque) at 4 °C for 1 h.
Subsequently, samples were incubated with the primary antibodies Anti-Myosin
Heavy Chain mouse monoclonal antibody (MF20, #14-6503, eBioscience) (1:800),
Anti-Dysferlin rabbit monoclonal antibody (#ab124684, Abcam) (1:200) in 10%
Blocking One/PBS solution containing 0.2% Triton X-100 at 4 °C overnight. After a
washing step, cells were incubated for 1 h at RT with the secondary antibodies
Alexa Fluor 568 Goat anti-Mouse IgG1 (#A21124, Thermo Fisher) (1:500) and
Alexa Fluor 488 Goat anti-Rabbit IgG (#A11034, Thermo Fisher) (1:500) in 10%
Blocking One/PBS solution containing 0.2% Triton X-100 and DAPI (1:5000).
Samples were observed with a BZ-X700 (Keyence).
Erythroid differentiation. For differentiation towards erythroid cells the protcols
by Ohta et al. and Niwa et al.34,56 were modified as follows. Briefly, before the start
of erythroid cell differentiation hiPSCs were prepared at clonal density (~400 cells)
in a 10 cm cell culture dish and cultured for about 7 days as described above, until
the colonies reached a size between 750–1000 µm in diameter. The erythroid dif-
ferentiation (Fig. 4d) was started by changing the medium to Essential 8 (E8;
Gibco) containing 80 ng/mL VEGFA (R&D system), 2 µM CHIR99021 (Merck)
and 80 ng/mL BMP4 (R&D system). During the entire differentiation cells were
kept at 37 °C in 5% O2 hypoxic condition. After 2 days of culture, the medium
was changed to Essential 6 (E6, Gibco) containing 50 ng/mL SCF (R&D system),
80 ng/mL VEGFA, 25 ng/mL bFGF (Wako) and 2 µM SB431542 (Milltenyi). From
day 4 onwards, cells were cultured in Stemline II medium (Sigma) containing 50
ng/mL SCF and 10 U/mL Erythopoietin (EPO, Merck). In addition, from day 4
until day 21, 50 ng/mL IL-6 (R&D system) were added to the medium. Further-
more, from day 4 until day 10, samples were cultured in 50 ng/mL IL-3 (R&D
system), 5 ng/mL TPO (R&D system) and 50 ng/mL Flt3/Flk2 (FI3, R&D system).
Also, from day 4 until day 6 80 ng/mL VEGFA were added to the medium. On day
10 and day 17, cells were dissociated by pipetting through a cell strainer and
passaged into a suspension culture at 5 × 104 cells/mL. On day 26, erythroid dif-
ferentiation and Protoporphyrin IX (PPIX) expression were confirmed by flow
cytometry and ALAS2 and FECH gene expression were measured by qRT-PCR as
described below. In addition, the amount of PPIX was confirmed using ethyl-
acetate/acetic acid extraction and resuspension in 1.5 mol/L HCl, as described35.
The fluorescence of the cell extract was measured using the EnVision (PE) with
photometric filters 590/7 (2100–5500; PE) and 420 nm optical filter (2100–5400;
PE) and compared to a PPIX (Frontier Scientific) standard dilution curve.
Flow cytometry. For measurement of mCherry fluorescence intensities, 3.0 × 105
cells were resuspended in FACS buffer (PBS containing 2% FBS), filtered through a
cell strainer and analyzed using a BD LSRFortessa Cell Analyzer (BD Biosciences)
with BD FACS Diva software (BD Biosciences).
For the confirmation of erythroid differentiation, 1 × 105 cells were stained with
anti-human CD235a-FITC (#349103, Biolegend, 1:20) and CD71-APC (#334107,
Biolegend, 1:20) in a total volume of 10 µL FACS buffer containing 0.5 µL Human
TruStain FcXTM (biolegend). Isotype controls were conducted using FITC and
APC Mouse IgG2a antibodies (#400209 and #400221, Biolegend). After a 20 min
incubation on ice, the samples were washed with 100 µL PBS containing 0.5 µg/mL
DAPI. Finally, the cells were resuspended in 100 µL FACS buffer and passed
through a cell strainer for analysis on a BD FACS ARIA II Cell Sorter (BD
Biosciences) with the BD FACS Diva Software version 8.0.1 (BD Biosciences).
For measurement of PPIX fluorescence intensities, which displays an
autofluorescence with a peak at 632 nm when excited at 409 nm57, the Qdot® 605
filter setting (excitation 405 nm, emission 610 nm+ /− 20 nm) of the BD FACS
ARIA II Cell Sorter was used.
Flow cytometry data were analyzed by FlowJo software v9.7.6 or higher
(Tree Star).
qRT-PCR. Total RNA was isolated from bulk cell populations on day 26 of ery-
throid cell differentiation using the RNeasy Plus Mini Kit (Qiagen) according to the
manufacturer’s instructions. For cDNA synthesis, 100 ng of RNA were reverse
transcribed using the SuperScript III First Strand Synthesis System (Invitrogen)
following the manufacturer’s instructions. For qRT-PCR analysis the SYBR Premix
ExTaq II (Takara) was applied according to the manufacturer’s instructions. The
analysis was conducted using the QuantStudio 3 (Thermo Fisher Scientific).
Human GAPDH was used to normalize the expression levels of the target tran-
scripts. qRT-PCR primers are listed in Supplementary Table 7.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The results on the dbSNP and ClinVar deletions can be explored in the web application
https://mhcut-browser.genap.ca/. The scripts from this analysis are available on the
GitHub repository at https://github.com/WoltjenLab/MHcut and the dataset was
deposited on Figshare at https://doi.org/10.6084/m9.figshare.9118364.v1. Source data is
available in the Source Data file The data that support the findings of this study are also
available from the corresponding author upon request. The pX459v2 plasmid can be
accessed via Addgene (#62988).
Code availability
MHcut is written in Python and available at the Python Package Index repository (PyPI),
on Zenodo at https://doi.org/10.5281/zenodo.3403353 and on GitHub at https://github.
com/WoltjenLab/MHcut. A Docker container is also provided.
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